China Merchants Securities: Haixi New Drug (02637.HK) HX9428 is expected to fill the blue ocean of oral treatment for nAMD

Zhitong Finance APP has learned that China Merchants Securities has issued a research report stating that Haixi New Drug's (02637.HK) oral innovative drug for fundus diseases, HX9428, is expected to address clinical treatment pain points, with broad potential market space, and has initiated coverage with an "Overweight" rating. The bank expects the company to achieve net profit attributable to shareholders of RMB 179 million / 207 million / 239 million from 2026 to 2028, corresponding to growth rates of 1% / 16% / 16%.